• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 5th November 2014

Spotlight on OHE: Adaptive Pathways, Economic Evaluation, Stated Preferences and Life-cycle Price Modelling

Medicines Adaptive Pathways: A Practical Strategy to Improve Patient Access to Medicines?   In September 2014 the Centre for Innovation in Regulatory Science held a workshop with invited regulators, health technology assessment (HTA) bodies and payers, industry and academics on…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Medicines Adaptive Pathways: A Practical Strategy to Improve Patient Access to Medicines?
 
In September 2014 the Centre for Innovation in Regulatory Science held a workshop with invited regulators, health technology assessment (HTA) bodies and payers, industry and academics on “Medicines Adaptive Pathways: A Practical Strategy to Improve Patient Access to Medicines?”. The aims of the workshop were to discuss new regulatory approaches to accelerating medicines availability, and suggest recommendations on how best to ensure success of new Facilitated Regulatory Pathways.
 
OHE’s Adrian Towse presented an academic perspective, arguing that a commercial model for an adaptive pathway required a form of coverage with evidence development (often called Managed Entry Agreements or Performance Based Risk Sharing Arrangements), along with a transformation in evidence collection costs through electronic health records (EHRs), disease registries, and methods evolution. Regulatory / HTA / company interaction on post-launch evidence requirements would be required. The company perspective was presented by Dr Jens Grueger; Hoffmann-La Roche, Switzerland.
 

Adaptive licensing cirs_akt_oct2014 from Office of Health Economics
For additional information please contact Adrian Towse at OHE.
 
Models for Health Economic Evaluation – a European perspective
 
OHE’s Jorge Mestre-Ferrandiz delivered a presentation in Lisbon on 1st October during the conference “Access to Innovation – A conditioned reality”. This conference was part of Apifarma’s Cycle of Conferences “Saber Investir, Saber Inovar”. The presentation began with a discussion of the current challenges/issues around the innovation landscape, and moved on to look closely at models of health economic evaluation in France, Germany and the UK. This presentation can be watched here http://www.youtube.com/watch?v=AyoScR9BjuU, from 00:29:27 to 1:28:00.
 

Antibiotics and the Economics of Innovation from Office of Health Economics

For additional information please contact Jorge Mestre-Ferrandiz at OHE.

 
Using stated preferences to guide health care resource allocation decisions
 
Speaking in London on 10th October 2014 OHE’s Koonal Shah gave a presentation as part of the Department of Health’s Speakeasy seminar series. Koonal provided a general introduction to how cost-effectiveness and analyses based on the quality-adjusted life year (QALY) are used to guide HTA decisions in the UK. He then reviewed the debate on whether all QALYs are of equal social value, focusing on the research question of whether society places special value on QALYs accruing to patients near the ends of their lives. A mixed picture emerges from the empirical literature, with some studies reporting evidence of public support for an end of life premium and other studies reporting the opposite.
 

Using Stated Preferences to Guide Health Care Resource Allocation Decisions from Office of Health Economics
For additional information please contact Koonal Shah at OHE.
 
Incorporating life-cycle price modelling into pharmaceutical cost-effectiveness analysis
 
OHE’s Michele Pistollato delivered a presentation on pharmaceutical life-cycle price modelling at the third annual Pharmaccess Leaders Forum held in Berlin from 8-10 October 2014. Michele’s presentation explained life-cycle pricing and why it is important that it is considered when performing cost-effectiveness analysis. Michele noted that neglecting life-cycle pricing in such analyses could lead to some cost-effective technologies not being recommended for reimbursement. This is therefore a key topic for HTA bodies and manufacturers.
 

Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Analysis from Office of Health Economics
Michele presented on the same theme at the 19th Annual Conference of the Italian Health Economics Association (AIES), which was held in Venice on 27th and 28th October. The topic of the conference was the financing of healthcare and welfare models in the era of longevity. 
For additional information please contact Michele Pistollato at OHE.
  • Health Technology Assessment…
  • Pricing and Reimbursement

Related News

  • News
  • November 2021

Opportunity Cost in Health Care: a Favourite Research Topic for OHE

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!